ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech firm Rubius raises $120 million

by Michael McCoy
June 26, 2017 | APPEARED IN VOLUME 95, ISSUE 26

Rubius Therapeutics, a Cambridge, Mass.-based developer of red-blood-cell-based therapies, has raised $120 million in a financing round that included its founding investor, Flagship Pioneering, as well as other investors. Rubius engineers red blood cells to express enzymes, agonists, antagonists, and other proteins. Launched in 2014, the company says its lead programs include enzyme replacement therapies and therapies targeting cancer. It expects to start human trials in 2018.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment